Literature DB >> 27602138

Targeted silencing of CXCR4 inhibits epithelial-mesenchymal transition in oral squamous cell carcinoma.

Yuansheng Duan1, Shu Zhang1, Longlong Wang2, Xuan Zhou1, Qinghua He1, Su Liu1, Kai Yue1, Xudong Wang1.   

Abstract

Aberrant overexpression of C-X-C chemokine receptor type 4 (CXCR4) is a critical event during tumor metastasis. It has been previously reported that the expression of CXCR4 is linked with epithelial-mesenchymal transition (EMT) in oral squamous cell carcinoma (OSCC) tissues derived from patients. The present study addresses the role of CXCR4 in EMT in tongue squamous cell carcinoma (TSCCA) cells in vitro and in xenograft models. Small interfering (si) RNA sequences targeting the CXCR4 gene were transfected into TSCCA cells. Cell migration, invasion, apoptosis and EMT markers were determined in TSCCA cells using wound healing and Transwell assays, Annexin V/propdidum iodide double staining and western blot analysis, respectively. In vivo, tumor growth was assessed by subcutaneous inoculation of cells into BALB/c nude mice. Phenotypic EMT markers and regulatory factors were detected in the tumor tissues derived from the mice. In vitro, silencing of CXCR4 expression suppressed cell migration and invasion, and induced apoptosis. The protein expression of the EMT-associated markers N-cadherin and matrix metalloproteinases 2/9 were attenuated, while E-cadherin was increased. In vivo, CXCR4 siRNA inhibited tumor growth, and EMT-associated proteins had similar expression patterns to the experimental results observed in vitro. In conclusion, the present study demonstrated that CXCR4 silencing suppressed EMT in OSCC, thus affecting tumor metastasis.

Entities:  

Keywords:  CXCR4; epithelial-mesenchymal transition; knockdown; metastasis; oral squamous cell carcinoma

Year:  2016        PMID: 27602138      PMCID: PMC4998519          DOI: 10.3892/ol.2016.4838

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  The effect of CXCR4 silencing on epithelial-mesenchymal transition related genes in glioma U87 cells.

Authors:  Yu Zhu; Ping Yang; Qin Wang; Jingyi Hu; Jing Xue; Guo Li; Guodong Zhang; Xu Li; Wei Li; Chunlei Zhou; Meng Zhao; Dong Wang
Journal:  Anat Rec (Hoboken)       Date:  2013-10-23       Impact factor: 2.064

Review 2.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Han Liu; Jianjun Lei; Wanxing Duan; Kruttika Bhat; Fengfei Wang; Erxi Wu; Zheng Wang
Journal:  Cancer Lett       Date:  2012-03-23       Impact factor: 8.679

5.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

Review 6.  Metastasis of squamous cell carcinoma of the oral tongue.

Authors:  Daisuke Sano; Jeffrey N Myers
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

7.  The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes.

Authors:  Francisco Valdés; Alberto M Alvarez; Annamaria Locascio; Sonia Vega; Blanca Herrera; Margarita Fernández; Manuel Benito; M Angela Nieto; Isabel Fabregat
Journal:  Mol Cancer Res       Date:  2002-11       Impact factor: 5.852

Review 8.  Epithelial to mesenchymal transition in head and neck squamous cell carcinoma.

Authors:  Ashley Smith; Theodoros N Teknos; Quintin Pan
Journal:  Oral Oncol       Date:  2012-11-19       Impact factor: 5.337

9.  Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Authors:  Stephanie J Gros; Nina Kurschat; Astrid Drenckhan; Thorsten Dohrmann; Evelyn Forberich; Katharina Effenberger; Uta Reichelt; Robert M Hoffman; Klaus Pantel; Jussuf T Kaifi; Jakob R Izbicki
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

10.  Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research.

Authors:  S G Patel; M Amit; T C Yen; C T Liao; P Chaturvedi; J P Agarwal; L P Kowalski; A Ebrahimi; J R Clark; C R Cernea; S J Brandao; M Kreppel; J Zöller; D Fliss; E Fridman; G Bachar; T Shpitzer; V A Bolzoni; P R Patel; S Jonnalagadda; K T Robbins; J P Shah; Z Gil
Journal:  Br J Cancer       Date:  2013-09-24       Impact factor: 7.640

View more
  11 in total

Review 1.  Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.

Authors:  Wiam El Kheir; Bernard Marcos; Nick Virgilio; Benoit Paquette; Nathalie Faucheux; Marc-Antoine Lauzon
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

Review 2.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

3.  The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.

Authors:  Qing-Ling Yang; Ling-Yu Zhang; Hai-Feng Wang; Yu Li; Yue-Yue Wang; Tian-Tian Chen; Meng-Fen Dai; Hai-Hua Wu; Su-Lian Chen; Wen-Rui Wang; Qiong Wu; Chang-Jie Chen; Cong-Zhao Zhou
Journal:  Oncotarget       Date:  2017-06-06

Review 4.  RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy.

Authors:  Smaranda Buduru; Alina-Andreea Zimta; Cristina Ciocan; Cornelia Braicu; Diana Dudea; Alexandra Iulia Irimie; Ioana Berindan-Neagoe
Journal:  Int J Nanomedicine       Date:  2018-06-08

5.  Tumor-associated neutrophils (TANs) in human carcinoma-draining lymph nodes: a novel TAN compartment.

Authors:  Silvia Lonardi; Francesco Missale; Stefano Calza; Mattia Bugatti; Raffaella Vescovi; Bresciani Debora; Ravindra Uppaluri; Ann Marie Egloff; Davide Mattavelli; Davide Lombardi; Luisa Benerini Gatta; Olivia Marini; Nicola Tamassia; Elisa Gardiman; Marco A Cassatella; Patrizia Scapini; Piero Nicolai; William Vermi
Journal:  Clin Transl Immunology       Date:  2021-02-16

6.  CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.

Authors:  Thomas Artur Werner; Christina Maria Forster; Levent Dizdar; Pablo Emilio Verde; Katharina Raba; Matthias Schott; Wolfram Trudo Knoefel; Andreas Krieg
Journal:  J Cancer       Date:  2018-02-27       Impact factor: 4.207

7.  Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.

Authors:  Xiaohui Yang; Shuai Wang; Weihua Yu; Yixiong Zheng; Yulian Wu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

8.  CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.

Authors:  Jiyang Xue; Ruixiang Li; Dingding Gao; Fenghua Chen; Hongjuan Xie
Journal:  Int J Nanomedicine       Date:  2020-08-07

9.  Effects of insulin-like growth factor binding protein 3 on cell growth and tumorigenesis in oral squamous cell carcinoma.

Authors:  Hong-Yuan Xu; Dong-Wang Zhu; Lai-Ping Zhong; Zhi-Yuan Zhang; Cheng-Zhe Yang; Xiao Yang; Peng Zhang
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

10.  Bioinformatics analysis reveals that ANXA1 and SPINK5 are novel tumor suppressor genes in patients with oral squamous cell carcinoma.

Authors:  Hua-Tao Wu; Wen-Tian Chen; Wen-Jia Chen; Chun-Lan Li; Jing Liu
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.